Cardiff Oncology to Participate in September 2026 Conferences

Cardiff Oncology (CRDF) will participate in two conferences in September 2026 featuring Mani Mohindru, Ph.D.

Rhea-AI Summary

Cardiff Oncology (CRDF) will participate in two conferences in September 2026 featuring Mani Mohindru, Ph.D. The company will present at the 8th Annual RAS-Targeted Drug Development Summit on Tuesday, September 8 at 9:00 AM ET, discussing PLK1-targeted therapy in RAS mutant metastatic colorectal cancer, and at the H.C. Wainwright 28th Annual Global Investment Conference on Monday, September 14 at 10:00 AM ET for a fireside chat. Slides and, for H.C. Wainwright, a live webcast and replay will be available via the “Events” section of the Cardiff Oncology website.

Market Context

Insiders bought 1,498,001 shares during the analyzed 90-day period. That net-buying context compleme...

Analysis

Insiders bought 1,498,001 shares during the analyzed 90-day period. That net-buying context complements the scheduled management appearances, but the notice provides no new operating or clinical data, leaving substantive updates as the key unresolved factor.

Key Figures

Announcement date: September 2, 2026 Upcoming conferences: 2 conferences Summit edition: 8th Annual +5 more

8 metrics

Announcement date September 2, 2026 Article dateline

Upcoming conferences 2 conferences September 2026 participation schedule

Summit edition 8th Annual RAS-Targeted Drug Development Summit

First event date September 8 RAS-Targeted Drug Development Summit

First event time 9:00 AM ET Tuesday, September 8 presentation

Conference edition 28th Annual H.C. Wainwright Global Investment Conference

Second event date September 14 H.C. Wainwright Global Investment Conference

Second event time 10:00 AM ET Monday, September 14 fireside chat

Historical Context

5 past events · Latest: Aug 11 (Neutral)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Aug 11	Second-quarter earnings	Neutral	-5.7%	Quarterly results and business update were followed by a 5.69% decline.
Jul 15	Registered direct offering	Negative	-32.1%	A $10 million registered direct offering was followed by a 32.11% decline.
Jun 02	Positive Phase 2 data	Positive	+2.0%	Positive randomized Phase 2 results were followed by a 2.03% gain.
Jun 01	Healthcare conference participation	Neutral	+2.0%	Jefferies conference participation was followed by a 2.03% gain.
May 21	Clinical data webcast	Neutral	-0.6%	A webcast announcement for updated Phase 2 data preceded a 0.56% decline.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Positive clinical data and offering news aligned with subsequent price reactions, while conference and webcast announcements produced mixed reactions.

Key Terms

plk1 inhibition, ras mutant metastatic colorectal cancer

2 terms

plk1 inhibition medical

"a clinical-stage biotechnology company leveraging PLK1 inhibition"

PLK1 inhibition means blocking the activity of the enzyme Polo‑like kinase 1, a protein that helps cells divide. For investors, it signals a drug approach aimed at slowing or stopping fast‑growing tumors by disrupting the cell’s “division machinery,” but it also raises safety and trial‑success questions because the same process is important in healthy tissues; clinical results and side‑effect profiles drive the investment impact.

ras mutant metastatic colorectal cancer medical

"PLK1 Targeted Therapy to Transform Outcomes in RAS Mutant Metastatic Colorectal Cancer"

Colorectal cancer that has spread beyond the original tumor site to other organs (metastatic) and carries a mutation in a RAS-family gene, most commonly KRAS or NRAS. RAS mutations change how cancer cells grow and respond to certain targeted drugs, so they directly affect which treatments are likely to work, how clinical trials are designed, and the commercial prospects of therapies aimed at this patient group—think of it as a distinct subtype that guides medical and development choices.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SAN DIEGO, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that Mani Mohindru, Ph.D. will participate in two upcoming conferences.

Details of the company’s participation are as follows:

• 8^th Annual RAS-Targeted Drug Development Summit
  
  
  • Advancing PLK1 Targeted Therapy to Transform Outcomes in RAS Mutant Metastatic Colorectal Cancer; Tuesday, September 8 at 9:00 AM ET
    
    
• H.C. Wainwright 28^th Annual Global Investment Conference
  
  
  • Fireside Chat; Monday, September 14 at 10:00 AM ET
    
    

After the conclusions of these events, interested parties can access slides by visiting the “Events” section of the Cardiff Oncology website. In addition, for the H.C. Wainwright conference, interested parties can register for and access the live webcast for the conference by visiting the “Events” section of the Cardiff Oncology website. That webcast replay will be available after the conclusion of the presentation.

About Cardiff Oncology, Inc.
Cardiff Oncology is a clinical-stage biotechnology company advancing innovative cancer treatments focused on PLK1 inhibition, a validated oncology target with practice-changing potential. Our lead asset, onvansertib, is a highly specific, oral PLK1 inhibitor currently being evaluated in a Phase 2 trial for first-line treatment of RAS-mutated metastatic colorectal cancer (“mCRC”), addressing a large, underserved patient population with high unmet need. Onvansertib is also under investigation in other PLK1-driven cancers through ongoing investigator-initiated trials and has shown robust single-agent clinical activity in hard-to-treat tumors. By targeting tumor vulnerabilities, we aim to overcome treatment resistance and deliver improved clinical outcomes for patients.

For more information, please visit https://www.cardiffoncology.com.

Investor Contact: 
Candice Masse 
Astr Partners 
candice.masse@astrpartners.com 

Media Contact:
Amy Bonanno
Lyra Strategic Advisory
abonanno@lyraadvisory.com

FAQ

What conferences will Cardiff Oncology (CRDF) attend in September 2026?

Cardiff Oncology will participate in the 8th Annual RAS-Targeted Drug Development Summit and the H.C. Wainwright 28th Annual Global Investment Conference in September 2026, with presentations featuring Mani Mohindru, Ph.D.

When is Cardiff Oncology presenting at the 8th Annual RAS-Targeted Drug Development Summit 2026?

Cardiff Oncology is scheduled to present at the 8th Annual RAS-Targeted Drug Development Summit on Tuesday, September 8 at 9:00 AM ET, focusing on advancing PLK1-targeted therapy in RAS mutant metastatic colorectal cancer.

What is the topic of Cardiff Oncology’s presentation at the RAS-Targeted Drug Development Summit 2026 (CRDF)?

Cardiff Oncology will discuss advancing PLK1-targeted therapy to transform outcomes in RAS mutant metastatic colorectal cancer at the 8th Annual RAS-Targeted Drug Development Summit.

When is Cardiff Oncology’s fireside chat at the H.C. Wainwright 28th Annual Global Investment Conference 2026?

Cardiff Oncology’s fireside chat at the H.C. Wainwright 28th Annual Global Investment Conference is scheduled for Monday, September 14 at 10:00 AM ET.

How can investors access Cardiff Oncology’s slides and webcasts for the September 2026 conferences?

After the conferences, slides will be available in the “Events” section of the Cardiff Oncology website. For the H.C. Wainwright conference, investors can also register for and access a live webcast and replay through the same Events section.